Prime Medicine, Inc. (PRME)

↓ Download CSV

CIK 0001894562 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Prime Medicine, Inc. reported revenue of $4.63M, up 55.3% from the prior year. The company ran a net loss, with a net margin of -4342.4%. It held $342.73M in total assets against $221.87M in total liabilities.

Key ratios (FY2025)

-4498.1%
Operating margin
-4342.4%
Net margin
-166.4%
Return on equity
+55.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$4.63M$2.98M$0$0$0$5.21M
Operating Income-$208.35M-$202.47M-$204.79M-$116.54M-$84.47M-$932.0K
Net Income-$201.14M-$195.88M-$198.13M-$121.82M-$165.37M-$3.41M
EPS (Diluted)$-1.35$-1.65$-2.18$-4.19$-14.19$-1.91
Total Assets$342.73M$297.51M$193.85M$360.31M$301.86M
Total Liabilities$221.87M$144.36M$60.78M$44.04M$62.30M
Shareholders' Equity$120.87M$153.15M$133.07M$316.27M-$156.24M$2.34M-$2.60M
Cash & Equivalents$63.03M$182.48M$41.57M$187.62M$185.42M$36.98M
Operating Cash Flow-$162.56M-$122.86M-$165.41M-$131.83M-$34.08M-$5.54M
Capital Expenditures$4.53M$7.29M$8.72M$16.09M$4.15M$639.0K
Shares Outstanding148.76M118.60M90.97M33.89M12.97M2.64M